Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human β-glucuronidase for antibody-directed enzyme prodrug therapy

Blood

Volumn 92, Issue 1, 1998, Pages 184-190

  Haisma, Hidde J ^a   Fleur Sernee, M ^b   Hooijberg, Erik ^b   Brakenhoff, Ruud H ^b   Meulen Muileman, Ida H V D ^b   Pinedo, Herbert M ^b   Boven, Epie ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; CD20 ANTIGEN; DOXORUBICIN; HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; N [4 DOXORUBICIN N CARBONYL(OXYMETHYL)PHENYL] O BETA GLUCURONYL CARBAMATE; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; DAUDI CELL; DRUG ACTIVATION; ENZYME ACTIVITY; GEL FILTRATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPRECIPITATION; MOLECULAR CLONING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION;

EID: 2642668461     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.1.184.413k26_184_190     Document Type: Article

References (31)

1. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023,1993
2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Vanderlelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540,1995
3. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL: I-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974,1996
4. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Bernstein ID: Phase II trial of 131-I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336,1995
5. Maloney DG, Lues TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillolopez A, Levy R: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457,1994
6. Bagshawe KD: Antibody-directed enzyme prodrug therapy. Drug Dev Res 34:220,1995
7. Knox RJ, Connors TA: Antibody-directed enzyme prodrug therapy. Clin Immunother 3:136,1995
8. Senter PD, Wallace PM, Svensson HP, Vrudhula VM, Kerr DE, Heistrom I, Heistrom KE: Generation of cytotoxic agents by targeted enzymes. Bioconjug Chem 4:3,1993
9. Haisma HJ, Boven E, Van Muijen M, De Jong J, Van der Vijgh WJF, Pinedo HM: A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer 66:474,1992
10. Haisma HJ, Van Muijen M, Pinedo HM, Boven E: Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer. Cell Biophys 24/25:185,1994
11. Hooijberg E, Sein JJ, Van den Berk PCM, Hekman A: Characterization of a series of isotype switch variants of a new CD20 monoclonal antibody. Hybridoma 15:23,1995
12. Hooijberg E, Sein JJ, Van den Berk PCM, Hart AAM, Van der Valk MA, Kast WM, Melief CJM, Hekman A: Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res 55:2627,1995
13. Shipley JM, Grubb JH, Sly WS: The role of glycosylation and phosphorylation in the expression of active human beta-glucuronidase. J Biol Chem 268:12193,1993
14. Houba PHJ, Leenders RGG, Boven E, Scheeren JW, Pinedo HM, Haisma HJ: Characterization of novel anthracycline prodrugs activated by human β-glucuronidase. Biochem Pharmacol 52:455,1996
15. Frohman MA, Dush MK, Martin GR: Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci USA 85:8998,1988
16. Caton AJ, Brownlee GG, Staudt LM, Gerhard W: Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemaglutinin. EMBO J 5:1577,1986
17. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R: Protein engineering of antibody binding sites, recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879,1988
18. Oshima A, Kyle JW, Miller RD, Hoffman JW, Powell PP, Grubb JH, Sly WS, Tropak M, Guise KS, Gravel RA: Cloning, sequencing and expression of cDNA for human beta-glucuronidase. Proc Natl Acad Sci USA 84:685,1987
19. Brakenhoff RH, Knippels EM, van Dongen GAMS: Optimization and simplification of expression cloning in eukaryotic vector/host systems. Anal Biochem 218:460,1994
20. Houba PHJ, Boven E, Haisma HJ: Improved characteristics of a human β-glucuronidase antibody conjugate after deglycosylation for use in antibody-directed enzyme prodrug therapy. Bioconjug Chem 7:606,1996
21. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680,1970
22. Klein E, Klein G, Nadkami JS, Nadkami JJ, Wigzell H, Clifford P: Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 28:1300,1968
23. Roffler SR, Wang SM, Chern JW, Yeh MY, Tung E: Anti-neoplasticglucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 42:2062,1991
24. Jain RK: Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol 60:85,1991
25. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB: Mouse/human chimeric monoclonal antibody in man, kinetics and immune response. Proc Natl Acad Sci USA 86:4220,1989
26. Meredith RF, LoBuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA: Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. J Nucl Med 32:1162,1991
27. Goshorn SC, Svensson HP, Kerr DE, Somerville JE, Senter PD, Fell HP: Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase. Cancer Res 53:2123,1993
28. Rodrigues ML, Presta LG, Kotts CE, Wirth C, Mordenti J, Osaka G, Wong WL, Nuijens A, Blackburn B, Carter P: Development of a humanized disulfide-siabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxonibicin prodrug. Cancer Res 55:63,1995
29. Bosslet K, Czech J, Lorenz P, Sedlacek HH, Schuermann M, Seeman G: Molecular and functional characterization of a fusion protein suited for tumour-specific prodrug activation. Br J Cancer 65:234,1992
30. Bosslet K, Czech J, Hoffman D: Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 54:2151,1994
31. Gehrmann MC, Opper M, Sedlacek HH, Bosslet K, Czech J: Biochemical properties of recombinant human β-glucuronidase synthesized in baby hamster kidney cells. Biochem J 301:821,1994